Androgen receptor plays a critical role in the development of primary as well as advanced
hormone-refractory prostate cancer. Therefore, ablation of androgen receptor from prostate …

Degradation of BCR-ABL oncoproteins by heat shock protein 90 (Hsp90) inhibitors in
chronic myelogenous leukemia is expected to overcome resistance to ABL tyrosine kinase …

Objective.—To review the current status of resistance to imatinib mesylate (IM) in patients
with chronic myelogenous leukemia, and the obstacles and opportunities presented by the …

The therapeutic approach to soft tissue sarcomas (STS) has evolved over the past two
decades based on the results from randomized controlled trials, which are guiding …

Despite advances in chemotherapy, radiotherapy and targeted drug development, cancer
remains a disease of high morbidity and mortality. The treatment of human cancer patients …

Tumors comprise genetically heterogeneous cell populations, whose growth and survival
depend on multiple signaling pathways. This has spurred the development of multitargeted …

2-Phenyl-7-phenylaminothieno [3, 2-b] pyridine-6-carbonitriles were recently reported to be
inhibitors of Src kinase activity. In this study we present structure− activity relationships for …

The BCR-ABL tyrosine kinase inhibitor imatinib has greatly improved the outcome for
patients with chronic myeloid leukaemia (CML). Unfortunately, mutations causing resistance …

Selective inhibitors of the Src family of protein tyrosine kinases have been developed as
therapeutic agents for human tumors, some of which are now in various stages of clinical …

Background Tyrosine kinase inhibitors (TKIs) are the recommended treatment for patients
with chronic myeloid leukemia (CML). The MDR1/ABCB1 gene plays a role in resistance to …